Zacks Investment Research
24 Sept 2026, 16:45 UTC · 1h ago
Verdict
Headline takes no side. We score ABBV +0.50 across three claims — strongly bullish.
+0.50strongly bullish
More positive than 68% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Pfizer's recently launched and acquired products grew operationally by 22% in Q1 2026 and 18% in Q2 2026.
Priced inanalysis of results from first half of 2026
So whatMaintaining double-digit growth in these segments is critical to offsetting the steep post-pandemic decline in COVID-19 product revenue for FY2026.
More positive than 77% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Pfizer's oncology revenues grew 5% in the first half of 2026.
Priced inanalysis of first half 2026 results
So whatSince oncology accounts for ~27% of total revenue, this 5% growth contributes roughly 1.35% to total top-line expansion.
More positive than 51% of claims this week
AbbVie's immunology segment accounts for approximately half of its total revenues.
Priced ingeneral portfolio description
More positive than 42% of claims this week
Which stocks this story touches
More positive than 68% of ticker scores this week
Strong performance of Skyrizi and Rinvoq successfully offsetting the loss of exclusivity for Humira.
More positive than 64% of ticker scores this week
Positive growth in recently launched products and oncology revenues, though transitioning away from COVID-19 dependency.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
Zacks Investment Research
1h ago
−0.3%
Price flat so far
$264.20 vs $265.08 close before publication (Sep 23) · not market-adjusted
ABBV chart →
